歌禮制藥-B(01672.HK):公司目前備有充足的ASC09╱利托那韋及利托那韋生產能力
格隆匯2月7日丨歌禮制藥-B(01672.HK)公佈,由浙江大學醫學院附屬第一醫院執行院長裘雲慶團隊發起的“比較ASC09╱利托那韋複方片和洛匹那韋╱利托那韋(克力芝)對於新型冠狀病毒感染的肺炎確診病例的療效及安全性的隨機、開放、多中心的臨牀試驗”已獲得浙江大學醫學院附屬第一醫院倫理委員會批准。
項目啟動會於昨日舉行,獲浙江省多地的研究人員參加。裘雲慶教授是傳染病診治國家重點實驗室副主任、中國醫師協會感染病科醫師分會常委以及浙江省藥物臨牀研究及評價技術重點實驗室主任。公司將就該臨牀試驗的進展及時告知公眾。
公告稱,公司目前備有充足的ASC09╱利托那韋及利托那韋生產能力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.